Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with procarbazine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving thalidomide together with procarbazine works in treating patients with recurrent or progressive malignant glioma.
Key facts
- Study ID
- NCT00079092
- Run by
- Wake Forest University Health Sciences
- People needed
- 18
- Starts
- 2004-01-01
- Expected to finish
- 2006-03-21
- Last updated by the study team
- 2021-09-09
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCOP - Central Illinois — Decatur, Illinois, United States
- CCOP - Southeast Cancer Control Consortium — Goldsboro, North Carolina, United States
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
- CCOP - Greenville — Greenville, South Carolina, United States
- CCOP - Upstate Carolina — Spartanburg, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.